Top

Published in:

01-03-2012 | Head and Neck Cancer (T Day, Section Editor)

mTOR Inhibitors and its Role in the Treatment of Head and Neck Squamous Cell Carcinoma

Authors: Shaun A. Nguyen, M.D., David Walker, B.S., M. Boyd Gillespie, M.D., J. Silvio Gutkind, PhD., Terry A. Day, M.D.

Published in: Current Treatment Options in Oncology | Issue 1/2012

Opinion statement

Head and neck squamous cell carcinomas (HNSCC) represent 6% of all cancers diagnosed each year in the United States, affecting approximately 43,000 new patients and resulting in approximately 12,000 deaths. Currently, three main rapalogs exist for the treatment of cancer: CCI-779 (temsirolimus), RAD001 (everolimus), and AP235373 (deforolimus). Clinicians managing HNSCC need to be aware of the three rapalogs. Extensive evidence has shown rapamycin-analogs to be effective agents in the treatment of a number of solid tumors. While extensive preclinical data suggests that HNSCC would be an appropriate tumor type to benefit from inhibition of the mTOR pathway, limited clinical data is yet available to support this. Numerous phase II trials evaluating mTOR inhibitors for use in HNSCC are currently recruiting patients.

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;caac.20073.

Jemal A, Thun MJ, Ries LAG, et al. Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control 23 2008;1000.

Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12:9–22.PubMedCrossRef

Amornphimoltham P, Sriuranpong V, Patel V, et al. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma. Clin Cancer Res. 2004;10:4029–37.PubMedCrossRef

Molinolo AA, Hewitt SM, Amornphimoltham P, et al. Dissecting the Akt/Mammalian target of Rapamycin signaling network: emerging results from head and neck cancer tissue array initiative. Clin Canc Res. 2007;17:4964–73.CrossRef

Nathan CO, Amirghahari N, Abreo F, et al. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/Mammalian target of Rapamycin pathway. Clin Cancer Res. 2004;10:5820–7.PubMedCrossRef

Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol. 2005;16:525–37.PubMedCrossRef

Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol. 2004;22:2954–63.PubMedCrossRef

Zoncu R, Efeyan A, Sabatini D. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev. 2011;12:21–35.CrossRef

10.

Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the Rictor-mTOR complex. Science. 2005;307:1098–101.PubMedCrossRef

11.

Gangloff Y-G, Mueller M, Dann SG, et al. Disruption of the mouse mTOR gene leads to early Postimplantation lethality and prohibits embryonic stem cell development. Mol Cell Biol. 2004;24:9508–16.PubMedCrossRef

12.

Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;123:471–84.CrossRef

13.

Raught B, Gingras A-C, Gygi SP, et al. Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI. EMBO J. 1999;19:434–44.CrossRef

14.

Kouvaraki MA, Liakou C, Paraschi A, et al. Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas. Surgery. 2011;150(6):1258–65.PubMedCrossRef

15.

Tang H, Hornstein E, Stolovich M, et al. Amino acid-induced translation of TOP mRNAs is fully dependent on phosphatidylinositol 3-kinase-mediated signaling, is partially inhibited by Rapamycin, and is independent of S6K1 and rpS6 phosphorylation. Mol Cell Biol. 2001;21:8671–83.PubMedCrossRef

16.

Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged Rapamycin treatment Inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22:159–68.PubMedCrossRef

17.

Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004;6:1122–8.PubMedCrossRef

18.

Liu L, Li F, Cardelli J, Martin K, Blenis J, Huang S. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene. 2006;25:7029–40.PubMedCrossRef

19.

Li B, Desai S, MacCorkle-Chosenek R, Fan L, Spencer D. A novel conditional AKT ‘survival switch’ reversibly protects cells from apoptosis. Gene Ther. 2002;9:233–44.PubMedCrossRef

20.

Castedo M. Sequential invovlemtn of CDK1, mtor and p53 in apoptosis induced by the HIV-1 envelope. EMBO J. 2002;21:4070–80.PubMedCrossRef

21.

Bjornsti M-A, Houghton PJ. The tor pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4:335–48.PubMedCrossRef

22.

Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a Novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004;22:2336–47.PubMedCrossRef

23.

Hidalgo M, Rowinsky EK. The rapamycin-sensitive singal transduction as a target pathway as a target for cancer therapy. Oncogene. 2000;19:6680–6.PubMedCrossRef

24.

Zimmerman JJ, Patat A, Parks V, Moirand R, Matschke K. Pharmacokinetics of Sirolimus (Rapamycin) in subjects with severe hepatic impairment. J Clin Pharmacol. 2008;48:285–92.PubMedCrossRef

25.

Brattstrom C, Wilczek H, Tyden G, Bottiger Y, Sawe J, Groth CG. Hyperlipidemia in renal transplant recipients treated with Sirolimus(Rapamycin). Transplantation. 1998;65:1272–4.PubMedCrossRef

26.

Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of Rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22:909–18.PubMedCrossRef

27.

Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, Interferon Alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–81.PubMedCrossRef

28.

Nathan C-AO, Amirghahari N, Sibley D, et al. In vivo and in vitro effect of CCI-779 a rapamycin analogue on HNSCC. AACR Meeting Abstracts. 2004;2004:850-c-1.

29.

Tanaka C, O’Reilly T, Kovarik JM, et al. Identifying optimal biologic doses of Everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol. 2008;26:1596–602.PubMed

30.

Tabernero J, Rojo F, Calvo E, et al. Dose- and schedule-dependent inhibition of the mammalian target of Rapamycin pathway with Everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol. 2008;26:1603–10.PubMedCrossRef

31.••

Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer. 2009;115:2438–46.PubMedCrossRef

32.

Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449–56.PubMedCrossRef

33.

Khariwala SS, Kjaergaard J, Lorenz R, Van Lente F, Shu S, Strome M. Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII). Laryngoscope. 2006;116(5):814–20.PubMedCrossRef

34.•

Patel V, Marsh CA, Dorsam RT, et al. Decreased Lyphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Research. 2011;71(22):7103–12.PubMedCrossRef

35.

Mita MM, Mita AC, Chu QS, et al. Phase I trial of the novel mammalian target of Rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 Days every 2 Weeks to patients with advanced malignancies. J Clin Oncol. 2008;26:361–7.PubMedCrossRef

36.

Hartford CM, Desai AA, Janisch L, et al. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of Deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009;15:1428–34.PubMedCrossRef

Title: mTOR Inhibitors and its Role in the Treatment of Head and Neck Squamous Cell Carcinoma
Authors: Shaun A. Nguyen, M.D.
David Walker, B.S.
M. Boyd Gillespie, M.D.
J. Silvio Gutkind, PhD.
Terry A. Day, M.D.
Publication date: 01-03-2012
Publisher: Current Science Inc.
Published in: Current Treatment Options in Oncology / Issue 1/2012
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-011-0180-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Opinion statement

Please log in to get access to this content

Other articles of this Issue 1/2012

Current Treatment Options for Metastatic Head and Neck Cancer

Neuroendocrine Pancreatic Tumors: Guidelines for Management and Update

Recurrent Salivary Gland Cancer

Emerging Therapeutic Targets in Diffuse Large B-Cell Lymphoma

Extent of Surgery for Papillary Thyroid Cancer: Preoperative Imaging and Role of Prophylactic and Therapeutic Neck Dissection

Post Transplant Lymphoproliferative Disorders: Risk, Classification, and Therapeutic Recommendations

Keynote webinar | Spotlight on antibody–drug conjugates in cancer